Fraiser Kansteiner

Despite a pair of clinical misfires in 2023, argenx has stuck by the thesis that its star drug Vyvgart, also known as efgartigimod, could tackle a wide array of autoimmune diseases linked to immuno

Riding high on Teva’s success under its recent “Pivot to Growth” strategy, chief executive Richard Francis—in his first year at the helm of the generics and innovative medicines hybrid—has emerged

After proving the merits of its drug delivery platform last year with the approval of Teva’s long-acting schizophrenia drug Uzedy, France’s Medincell has hooked another big-name partner.

Novo Nordisk is receiving pushback from a trio of lawmakers over its decision to discontinue its long-acting insulin product Levemir, which was due for a steep discount at the start of the new year.

The prospects for Vanda Pharmaceuticals’ 10-year-old circadian rhythm drug Hetlioz have grown that much dimmer after the U.S.

As the BIOSECURE Act threatens to upend relationships with Chinese contractors and western biopharma companies operating in the U.S., Novartis has elected not to adopt a “wait and see” attitude.

While Biogen's Chris Viehbacher figures the company is “turning the corner” after several recent setbacks—thanks in large part to accelerating launches of new drugs like Leqembi and Skyclarys—the CEO has admitted that there's still “a lot of work to do” as the pharma plugs ahead with its “Fit for Growth” savings initiative.

Even as new Sanofi drugs like Beyfortus and Altuviiio come into their own, the French pharma's immunology powerhouse Dupixent shows no signs of slowing down.

Just a few months after laying into CEOs from Bristol Myers Squibb, Merck & Co., and Johnson & Johnson about the high costs of their drugs, Sen.

Shortly after winning a stay on a COVID-19 vaccine patent lawsuit brought by Moderna, Pfizer and its German partner BioNTech are being dragged into another round of mRNA litigation by GSK.